Table 4. Treatment-Related AEs Clinically significant AEs for lenvatinib of any grade and of grade 3-5 occurred in 94 (91.3%) and 33 (32.0%) patients, respectively; hypertension was the most common ...

Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET ...

Clinical and genomic characterization of ERBB2-altered gallbladder cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84 ...

Results from this study suggested encouraging antitumor activity with an ORR of 68% and a median PFS of 9.0 months at the MTD of 4 mg BID. Therefore, lenvatinib administered at 4 mg BID was ...

Lenvatinib exerts its antitumor effects mainly by potently inhibiting activity of vascular endothelial growth factor receptor 1–3 (VEGFR1–3), fibroblast growth factor receptor 1–4 (FGFR1–4 ...

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug. Objective ...

The committee concluded that the relevant comparators for lenvatinib plus everolimus were axitinib, nivolumab and cabozantinib. 3.4 The main clinical evidence for lenvatinib plus everolimus came from ...

Eisai's model for lenvatinib included 4 health states (stable disease, response, progressive and death) whereas Bayer's model for sorafenib included only 3 health states (progression-free, progressed ...